[1]
|
Kupka, R.W., Altshuler, L.L., Nolen, W.A., Suppes, T., Luckenbaugh, D.A., Leverich, G.S., et al. (2007) Three Times More Days Depressed than Manic or Hypomanic in Both Bipolar I and Bipolar II Disorder. Bipolar Disorders, 9, 531-535. https://doi.org/10.1111/j.1399-5618.2007.00467.x
|
[2]
|
Silva, M.T., Zimmermann, I.R., Galvao, T.F. and Pereira, M.G. (2013) Olanzapine plus Fluoxetine for Bipolar Disorder: A Systematic Review and Meta-Analysis. Journal of Affective Disorders, 146, 310-318. https://doi.org/10.1016/j.jad.2012.11.001
|
[3]
|
Shen, Y.-C. (2018) Treatment of Acute Bipolar Depression. Tzu Chi Medical Journal, 30, 141-147. https://doi.org/10.4103/tcmj.tcmj_71_18
|
[4]
|
Suttajit, S., Srisurapanont, M., Maneeton, N. and Maneeton, B. (2014) Quetiapine for Acute Bipolar Depression: A Systematic Review and Meta-Analysis. Drug Design, Development and Therapy, 8, 827-838. https://doi.org/10.2147/dddt.s63779
|
[5]
|
Anderson, S.L. and Vande Griend, J.P. (2014) Quetiapine for Insomnia: A Review of the Literature. American Journal of Health-System Pharmacy, 71, 394-402. https://doi.org/10.2146/ajhp130221
|
[6]
|
Loebel, A., Xu, J., Hsu, J., Cucchiaro, J. and Pikalov, A. (2015) The Development of Lurasidone for Bipolar Depression. Annals of the New York Academy of Sciences, 1358, 95-104. https://doi.org/10.1111/nyas.12965
|
[7]
|
Fountoulakis, K.N., Gazouli, M., Kelsoe, J. and Akiskal, H. (2015) The Pharmacodynamic Properties of Lurasidone and Their Role in Its Antidepressant Efficacy in Bipolar Disorder. European Neuropsychopharmacology, 25, 335-342. https://doi.org/10.1016/j.euroneuro.2014.11.010
|
[8]
|
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., et al. (2014) Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 171, 160-168. https://doi.org/10.1176/appi.ajp.2013.13070984
|
[9]
|
Tocco, M., Newcomer, J.W., Mao, Y., Pikalov, A. and Loebel, A. (2020) Lurasidone and Risk for Metabolic Syndrome: Results from Short-and Long-Term Clinical Studies in Patients with Schizophrenia. CNS Spectrums, 26, 614-624. https://doi.org/10.1017/s1092852920001698
|
[10]
|
Leggio, G.M., Salomone, S., Bucolo, C., et al. (2013) Dopamine D3 Receptor as a New Pharmacological Target for the Treatment of Depression. European Journal of Pharmacology, 719, 25-33. https://doi.org/10.1016/j.ejphar.2013.07.022
|
[11]
|
Pinto, J.V., Saraf, G., Vigo, D., et al. (2020) Cariprazine in the Treatment of Bipolar Disorder: A Systematic Review and Meta-Analysis. Bipolar Disorders, 22, 360-371. https://doi.org/10.1111/bdi.12850
|
[12]
|
Antrim, A. (2012) FDA Approves Lumateperone for the Treatment of Bipolar Depression. https://www.pharmacytimes.com/view/fda-approves-lumateperone-for-the-treatment-of-bipolar-depression
|
[13]
|
Calabrese, J.R., Durgam, S., Satlin, A., Vanover, K.E., Davis, R.E., Chen, R., et al. (2021) Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. American Journal of Psychiatry, 178, 1098-1106. https://doi.org/10.1176/appi.ajp.2021.20091339
|
[14]
|
D’Souza, I., Durgam, S., Satlin, A., Davis, R.E., Kozauer, S.G., Chen, R., et al. (2021) Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial. CNS Spectrums, 26, 150-150. https://doi.org/10.1017/s1092852920002370
|
[15]
|
Malhi, G.S., Tanious, M., Das, P., Coulston, C.M. and Berk, M. (2013) Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs, 27, 135-153. https://doi.org/10.1007/s40263-013-0039-0
|
[16]
|
Fountoulakis, K.N., Grunze, H., Panagiotidis, P., et al. (2008) Treatment of Bipolar Depression: An Update. Journal of Affective Disorders, 109, 21-34. https://doi.org/10.1016/j.jad.2007.10.016
|
[17]
|
Gershon, S., Chengappa, K.R. and Malhi, G.S. (2009) Lithium Specificity in Bipolar Illness: A Classic Agent for the Classic Disorder. Bipolar Disorders, 11, 34-44. https://doi.org/10.1111/j.1399-5618.2009.00709.x
|
[18]
|
Sarai, S.K., Mekala, H.M. and Lippmann, S. (2018) Lithium Suicide Prevention: A Brief Review and Reminder. Innovations in Clinical Neuroscience, 15, 30-32.
|
[19]
|
唐瑛, 吕东升, 柳亭. 拉莫三嗪在双相情感障碍患者中的研究进展[J]. 内蒙古医学杂志, 2023, 55(3): 321-324, 328. https://doi.org/10.16096/J.cnki.nmgyxzz.2023.55.03.017
|
[20]
|
Geddes, J.R., Calabrese, J.R. and Goodwin, G.M. (2009) Lamotrigine for Treatment of Bipolar Depression: Independent Meta-Analysis and Meta-Regression of Individual Patient Data from Five Randomised Trials. British Journal of Psychiatry, 194, 4-9. https://doi.org/10.1192/bjp.bp.107.048504
|
[21]
|
Van der Loos, M.L., Mulder, P.G.H., Hartong, E.G., Blom, M.B., Vergouwen, A.C., de Keyzer, H.J., et al. (2009) Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression: A Multicenter, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Psychiatry, 70, 223-231. https://doi.org/10.4088/JCP.08m04152
|
[22]
|
Bloom, R. and Amber, K.T. (2017) Identifying the Incidence of Rash, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Patients Taking Lamotrigine: A Systematic Review of 122 Randomized Controlled Trials. Anais Brasileiros de Dermatologia, 92, 139-141. https://doi.org/10.1590/abd1806-4841.20175070
|
[23]
|
Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., Marangell, L.B., Wisniewski, S.R., Gyulai, L., et al. (2007) Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. New England Journal of Medicine, 356, 1711-1722. https://doi.org/10.1056/nejmoa064135
|
[24]
|
Gijsman, H.J., Geddes, J.R., Rendell, J.M., Nolen, W.A. and Goodwin, G.M. (2004) Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. American Journal of Psychiatry, 161, 1537-1547. https://doi.org/10.1176/appi.ajp.161.9.1537
|
[25]
|
Vieta, E., Martinez-Aran, A., Goikolea, J.M., Torrent, C., Colom, F., Benabarre, A., et al. (2002) A Randomized Trial Comparing Paroxetine and Venlafaxine in the Treatment of Bipolar Depressed Patients Taking Mood Stabilizers. The Journal of Clinical Psychiatry, 63, 508-512. https://doi.org/10.4088/jcp.v63n0607
|
[26]
|
Ramic, E., Prasko, S., Gavran, L. and Spahic, E. (2020) Assessment of the Antidepressant Side Effects Occurrence in Patients Treated in Primary Care. Materia Socio Medica, 32, 131-134. https://doi.org/10.5455/msm.2020.32.131-134
|
[27]
|
Fava, M., Rush, A.J., Thase, M.E., Clayton, A., Stahl, S.M., Pradko, J.F., et al. (2005) 15 Years of Clinical Experience with Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. Primary Care Companion for CNS Disorders, 7, 106-113. https://doi.org/10.4088/pcc.v07n0305
|
[28]
|
Popiolek, K., Bejerot, S., Brus, O., Hammar, A., et al. (2019) Electroconvulsive Therapy in Bipolar Depression-Effectiveness and Prognostic Factors. Acta Psychiatrica Scandinavica, 140, 196-204. https://doi.org/10.1111/acps.13075
|
[29]
|
Nguyen, T.D., Hieronymus, F., Lorentzen, R., McGirr, A. and Østergaard, S.D. (2021) The Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMs) for Bipolar Depression: A Systematic Review and Meta-Analysis. Journal of Affective Disorders, 279, 250-255. https://doi.org/10.1016/j.jad.2020.10.013
|